Building a Global Life Science Company in NZ

1. Building a Global Life Science Company in NZ

2. Unlocking Regenerative Healing

3. Regenerative Tissue Substitutes

4. US Soft Tissue Repair Millennium US Markets for Soft Tissue Repair, 2008

5. Platform Dura CMF Dental & Oral Cardiovascular Abdominal Wall Breast Pelvic Floor Gastrointestinal Joint Nerve Tendon/Ligament Extremities

6. Endoform & Cell cross-talk Lun, S et al. (2010). Biomaterials31(16): 4517-29. Schultz GS et al Wound Repair Regen 2011 Mar-Apr;19(2):134-148

7. >Angiogenesis Irvine et al (2011) In press.

8. Remodeled Endoform™ 4 x High magnification Day 7 Day 14 Day 42

9. Stronger

10. Endoform™ D T • partial and full thickness wounds • pressure ulcers • venous ulcers • chronic vascular ulcers • diabetic ulcers • tunnelled undermined wounds • traumatic wounds • surgical wounds

11. Clinical • Dr Jeremy Simcock (NZ) pilot study • 12 patients DFU’s and VU’s • Increased vascularity and granulation tissue formation • Dr Brock Liden (USA) • 19 participants with 24 wounds (DFU and VU) • Mean decrease in wound area at 12 weeks was 73.4%. • Mean time to complete closure was 6.8 weeks. • 50% closed at 12 weeks • Increased vascularity and granulation tissue formation • Dr Jeremy Simcock (NZ) • 5 patient tumor resection with single-stage split-thickness graft onto Endoform

12. Endoform™ R T • Soft Tissue Reconstruction Floden et al. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2011;96B(1):67-75.

13. Endoform™2.0 • Infection Control

14. Milestones

15. Competitive Advantage 1.0 rapid vascular in-growth, stimulates cell proliferation , completely remodeled & safe†

16. Competitive Advantage 1.0 Strong in thin formats, laminated for load bearing & persistence rapid vascular in-growth, stimulates cell proliferation , completely remodeled & safe†

17. Competitive Advantage 1.0 Simple and quick to use Strong in thin formats, laminated for load bearing & persistence rapid vascular in-growth, stimulates cell proliferation , completely remodeled & safe†

18. Competitive Advantage 1.0 Low COGs Simple and quick to use Strong in thin formats, laminated for load bearing & persistence rapid vascular in-growth, stimulates cell proliferation , completely remodeled & safe†

19. Competitive Advantage 1.5 Low COGs Ease to Use Robust Biology

25. High Contact Team Effort

28. Business Model Exceptional returns +/- Partners Product Format Orthopaedic Cardiovascular $$$$$ + Stem/Progenitor cells Strong positive cashflows - Partnered  + Bioactives Soft Tissue Reconstruction $$$  development & clinical complexity + Layers  Single Active Wound Care $

29. Business Model • Start simple, validate the opportunity, learn & iterate • Develop (r&D) and manufacture to produce strong positive cash flow • Partner with proven companies for sales and marketing • Pursue more complex applications for exceptional returns

30. NZ Factors

31. ??? Ingenuity

32. Rare & valuable resources

33. $???

34. RegenMed Factors

35. RegenMed Will lead to therapies that will fundamentally change current therapies and complement the use of pharmaceuticals, biologicals & medical devices because offers the opportunity to restore function and cure chronic conditions1 1. Mason C., Brindley, D.A., Culme-Seymour E.J. and Davie N.L. (2011).Cell therapy industry: billion dollar global business with unlimited potential. Regenerative Medicine, May 2011, Vol. 6(3), 265-272.

38. RegenMed • Devices/Therapeutics/Combinations • Mixed regulatory paths • Mixed business models • No dominant players • Interest from Big device & pharma • High growth and pricing potential

39. Comps

40. Summary • Strong platform, multiple products, unmet clinical need & large fast-growing markets • Attained no. of value accretive milestones & external validation • Revenue and cash-flow – WIP • Many challenges ahead - no set formula or prescription…